Reply

Affiliations

Comment

Jeffrey S Heier. Ophthalmology. 2021 Sep.

. 2021 Sep;128(9):e47-e48.

doi: 10.1016/j.ophtha.2021.04.030. Epub 2021 May 27.

¹ Ophthalmic Consultants of Boston, Boston, Massachusetts. Electronic address: jsheier@eyeboston.com.

No abstract available

Comment on

Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Monés J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, Holz FG, Korobelnik JF, Kim IK, Pruente C, Murray TG, Heier JS. Monés J, et al. Ophthalmology. 2021 Jul;128(7):1050-1059. doi: 10.1016/j.ophtha.2020.11.011. Epub 2020 Nov 15. Ophthalmology. 2021. PMID: 33207259 Clinical Trial.
Re: Monés et al.: Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER (Ophthalmology. 2021;128:1050-1059).
Shukla D. Shukla D. Ophthalmology. 2021 Sep;128(9):e47. doi: 10.1016/j.ophtha.2021.04.029. Epub 2021 May 28. Ophthalmology. 2021. PMID: 34053734 No abstract available.